Business Context and Reporting Period
Company: Zentalis Pharmaceuticals, Inc. (ZNTL)
Filing Type: Form 8-K (Current Report)
Date of Report: March 15, 2025
Reporting Period: The filing reports on events occurring on March 15, 2025, specifically regarding a press release and a presentation at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting held March 14–17, 2025.
Key Financial Metrics
This Form 8-K is a disclosure of non-financial events and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing discloses the following material events under Item 7.01 (Regulation FD Disclosure):
- Issuance of a press release on March 15, 2025 (Exhibit 99.1).
- Presentation of information at the 2025 SGO Annual Meeting on Women's Cancer in Seattle, Washington (Exhibit 99.2).
No material changes to financial position or operations are detailed within the text of this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release and an SGO presentation. The content of these exhibits is not included in the text of the 8-K itself, so specific guidance, outlook, or management commentary cannot be summarized from this document alone.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 7.01 and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor incorporated by reference in other filings except as expressly provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the announcement made on March 15, 2025.
- Review Exhibit 99.2 (2025 SGO Annual Meeting Presentation) for clinical data, trial updates, or strategic outlook presented at the conference.
- Verify the trading status of Common Stock (Symbol: ZNTL) on The Nasdaq Global Market following the release of this information.
- Confirm if subsequent filings (e.g., 10-Q or 10-K) incorporate the data from these exhibits for financial or operational updates.